← Compound index
RESEARCH FAMILY / GB-115

GB-115 & CCK analoguesГБ-115

A synthetic dipeptide derivative containing L-tryptophan, designed from cholecystokinin tetrapeptide (CCK-4). Human anxiety trials studied the oral formulation Ranquilon.

StressCognition
Source linked

What the studies found

Randomized study in people · 2024

220-person placebo trial: 70% versus 24.5% anxiety response

Primary ≥50% HARS response
77/110 (70.0%) versus 27/110 (24.5%)Day 29 ± 1p<0.0001
Response-rate difference
45.5 percentage pointsAbsolute difference, not a 45.5% relative reduction
HARS decrease · day 29
11.90 ± 4.88 versus 5.43 ± 5.03 pointsp<0.0001

At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.

More reported outcomes
Patients with adverse events
28/110 (25.5%) versus 16/110 (14.6%)p=0.063
Adverse-event counts
43 active-arm events; 21 placebo-arm eventsNo serious events or adverse-event discontinuations reported
Study notes · methods, sources and limitations

Participants or model 220 adults, 110 Ranquilon and 110 placebo; 28 days of treatment.

Important limitations

  • Neurasthenia and adjustment disorders; do not relabel this as a generalized-anxiety-disorder trial. Valenta-funded report with sponsor-affiliated authors; 28-day efficacy and safety require longer independent follow-up.

V.M. Bekhterev Review of Psychiatry and Medical Psychology. 58(4-2):78–99 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2023

168-person dose-finding trial: the 6 mg group outperformed placebo

Primary CGI-I response · 6 mg/day
57.1% versus 28.6% placeboDay 29p=0.0148
Primary CGI-I response · 3 / 9 mg/day
39.5% / 43.9%Neither significantly exceeded placebo

At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.

Study notes · methods, sources and limitations

Participants or model 168 randomized: 3 mg/day n=43, 6 mg/day n=42, 9 mg/day n=41, placebo n=42; 165 completed per protocol.

Analysis populations
168 intention-to-treat; 165 per protocol

Important limitations

  • Randomized double-blind study in neurasthenia/adjustment disorders; generalized anxiety disorder was excluded. Sponsor-affiliated investigators; four-week findings do not establish long-term benefit.

Clinical Pharmacology and Therapy. 32(4):36–40 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2026

2026 active-comparator trial reported higher response than Afobazol

Reported ≥50% HARS response
63.3% (62 patients) versus 49.0% (49 patients)Day 29p<0.043
Arm-level patients with adverse events
16/100 versus 12/100Overall count in abstract is inconsistent; arm-level figures retained as printedp=0.4150

The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).

Study notes · methods, sources and limitations

Participants or model 200 randomized: Ranquilon 100; Afobazol 100.

Important limitations

  • Active-comparator, open-label trial; this is not a blinded placebo comparison. The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 126(7):51–62 · Original journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About GB-115 & CCK analogues

Names in this research collection

GB-115 · Ranquilon · Rankvilon · Ранквилон · GB-101 · CCK-4 · Cholecystokinin

Identity / background source ↗

Research background

A synthetic CCK-4-related dipeptide derivative studied as Ranquilon in randomized human anxiety trials; related CCK-4 and stereochemical compounds are kept distinct.

CCK-4 / GB-115 / RANQUILON

From a panic-provoking peptide to an anxiety-drug candidate

CCK-4 can provoke panic symptoms in laboratory challenges. In one randomized, double-blind study of 36 healthy volunteers, panic occurred in 11%, 17% and 47% of challenges at increasing CCK-4 doses, and in none after placebo. Original challenge study →

GB-115 is a different molecule. Its developers used CCK-4 as a starting point for smaller peptide derivatives. In the 2007 rat experiments, derivatives containing L-tryptophan reduced anxiety-like behavior, while the D-tryptophan series increased it. GB-115 belongs to the L-series. Design and stereochemistry →

Which anxiety conditions were studied?

The early 31-person pilot enrolled people with generalized anxiety disorder. The larger phase II and III placebo trials instead enrolled adults with anxiety associated with neurasthenia or adjustment disorders. Those populations should retain their original diagnoses when interpreting the results.

The 2026 study compared Ranquilon with Afobazol openly. It adds active-comparator evidence, while the two earlier randomized, double-blind trials provide the inactive-placebo comparisons. Published receptor descriptions have changed over time; the design history alone does not establish receptor subtype selectivity.

Compare the placebo trials → · 2026 active-comparator report →

Compound class
Peptide research family
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Randomized placebo trials (168 and 220 participants), an open active-comparator trial (200), and pilot reports

Study methods

Phase II and III explicitly double-blind; phase IV compares active treatments openly

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Phase III adverse events: 28/110 active versus 16/110 placebo; short follow-up

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Interpretation and open questions

Placebo trials concern neurasthenia and adjustment disorders; the earlier GAD study was uncontrolled. The 2026 Afobazol comparison was open-label.

CCK receptor subtype claims, affinity and behavioral mechanism should be examined separately; a design origin alone does not settle the receptor target.

Explore the Russian peptide research map ↗

What remains unclear

The Phase IV report describes 62 responders as 63.3% of the sample despite 100 randomized participants. Its adverse-event totals also differ. The Phase II and III placebo comparisons concern neurasthenia and adjustment disorders. The CCK-4 challenge studies provide background on the model.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2019 · RU2709013C1 · GB-115: activating anxiolytic applicationUse · Improvement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 3

Findings described in words

The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.

Illustrative course
Improvement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 321 daysSingle selected case, not a controlled response rate
Clinical scale narrative
Reduced mental and autonomic anxiety symptoms reportedThe source cites before/after significance; exact values and denominators not entered
All reported results, comparisons and limitations →

Use. The patent proposes GB-115 as an activating anxiolytic.

The granted use is not independent confirmation of all clinical anxiety or cognition claims.

Publication
RU2709013C1 ↗ · 2019-12-13
Earliest priority / filing
2018-10-19 / 2018-10-19
Original applicant / assignee
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications

Use of amide n-(6-phenylhexanoyl) glycyl-l-tryptophane (gb-115) as an agent having anxiolytic properties with an activating component

Inventors: Григорий Георгиевич Незнамов; Сергей Борисович Середенин; Ольга Анатольевна Дорофеева; Марианна Вячеславовна Метлина.

RU2709013C1

Original patent PDF ↗

Read source review →

2016 · RU2602742C2 · GB-115: solid dosage formFormulation · 192% relative to the reference substance

Reported findings

The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.

Relative bioavailability
192% relative to the reference substanceA formulation-specific rat ratio; not absolute oral bioavailability or a human value
Elimination and residence
Half-life 44.75 minutes; mean residence time 68.32 minutes; elimination constant 0.0155/minRat pharmacokineticsParameters reported for the formulation
All reported results, comparisons and limitations →

Formulation. The claims concern a solid pharmaceutical form of GB-115 and formulation components.

Formulation protection is distinct from proof of clinical benefit or from the base-compound discovery claim.

Publication
RU2602742C2 ↗ · 2016-11-20
Earliest priority / filing
2013-12-13 / 2013-12-13
Original applicant / assignee
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имен В.В. Закусова"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition of n-(6-phenylhexanoyl)glycyl-l-tryptophan amide in solid dosage form

Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Константин Викторович Алексеев; Любовь Николаевна Грушевская; Лариса Геннадьевна Колик; Владимир Павлович Жердев; Надежда Михайловна Зайцева; Евгения Викторовна Блынская; Ксения Геннадьевна Турчинская; Наталья Викторовна Тихонова; Людмила Михайловна Гаевая; Марк Александрович Константинопольский; Светлана Семеновна Бойко.

RU2602742C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2019

GB-115: activating anxiolytic application — RU2709013C1

The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.

Illustrative course · Improvement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 3 · Single selected case, not a controlled response rate · 21 days

Study notes and original source
2019Patent / reported experimentsFull text available

GB-115: activating anxiolytic application — RU2709013C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Григорий Георгиевич Незнамов, Сергей Борисович Середенин, Ольга Анатольевна Дорофеева, Марианна Вячеславовна Метлина · RU2709013C1 · patent family RU2709013C1

The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.

Results and tables

Reported patent results

Findings described in words

The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.

GB-115 patent clinical anxiety observations and an illustrated 21-day case; full arm sizes and outcome-table values were not extracted.

Population or model GB-115 patent clinical anxiety observations and an illustrated 21-day case; full arm sizes and outcome-table values were not extracted.

Results · Clinical scale narrative, tolerability statement and illustrative patient example.
MeasureResultComparison, timing and statistics
Illustrative courseImprovement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 3Single selected case, not a controlled response rate · 21 days
Clinical scale narrativeReduced mental and autonomic anxiety symptoms reportedThe source cites before/after significance; exact values and denominators not entered
Reported tolerabilityNo listed sedative/muscle-relaxant or excessive-stimulation effects reportedLimited patent observation; not a comprehensive safety comparison

Selected cases and incompletely extracted group data do not independently confirm modern trial efficacy. Related clinical publications may describe the same development program.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
GB-115 patent clinical anxiety observations and an illustrated 21-day case; full arm sizes and outcome-table values were not extracted.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The granted use is not independent confirmation of all clinical anxiety or cognition claims.
  • Selected cases and incompletely extracted group data do not independently confirm modern trial efficacy. Related clinical publications may describe the same development program.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2016

GB-115: solid dosage form — RU2602742C2

The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.

Relative bioavailability · 192% relative to the reference substance · A formulation-specific rat ratio; not absolute oral bioavailability or a human value

Study notes and original source
2016Patent / reported experimentsFull text available

GB-115: solid dosage form — RU2602742C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Сергей Борисович Середенин, Татьяна Александровна Гудашева, Борис Михайлович Пятин, Нина Ивановна Авдюнина, Константин Викторович Алексеев, Любовь Николаевна Грушевская, Лариса Геннадьевна Колик, Владимир Павлович Жердев, Надежда Михайловна Зайцева, Евгения Викторовна Блынская, Ксения Геннадьевна Турчинская, Наталья Викторовна Тихонова, Людмила Михайловна Гаевая, Марк Александрович Константинопольский, Светлана Семеновна Бойко · RU2602742C2 · patent family RU2602742C2

The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.

Results and tables

Reported patent results

Reported findings

The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.

GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.

Population or model GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.

Results · Pharmacokinetic results and Table 2 narrative, with reported half-life and residence time.
MeasureResultComparison, timing and statistics
Relative bioavailability192% relative to the reference substanceA formulation-specific rat ratio; not absolute oral bioavailability or a human value
Elimination and residenceHalf-life 44.75 minutes; mean residence time 68.32 minutes; elimination constant 0.0155/minParameters reported for the formulation · Rat pharmacokinetics
Time profileA second maximum described around 40–60 minutes; detectable through 90 minutesThe proposed recirculation explanation is not directly proven

Rat exposure and behavior do not establish a superior human anxiolytic effect. The pharmacokinetic values cannot be transferred to a different product.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Formulation protection is distinct from proof of clinical benefit or from the base-compound discovery claim.
  • Rat exposure and behavior do not establish a superior human anxiolytic effect. The pharmacokinetic values cannot be transferred to a different product.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Randomized study in people · 2023

Ranquilon dose-finding in anxiety associated with neurasthenia and adjustment disorders: phase II trial

At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.

Study notes and original source
2023Randomized trialFull text available

Ranquilon dose-finding in anxiety associated with neurasthenia and adjustment disorders: phase II trial

GB-115 / Ranquilon (L-tryptophan dipeptide derivative) · Original journal publication

O. V. Goncharov, D. Ch. Mavani, A. A. Ledovskikh, L. A. Tsukurova, M. M. Gavrik, I. V. Balaban, A. A. Globenko, A. V. Kapashin, M. A. Pasko · Clinical Pharmacology and Therapy. 32(4):36–40

At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.

Results and tables

Reported findings and study design

At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.

Population or model 168 randomized: 3 mg/day n=43, 6 mg/day n=42, 9 mg/day n=41, placebo n=42; 165 completed per protocol.

Dose, route and schedule

Oral 3, 6 or 9 mg/day, split three times daily, or matching placebo for 28 days. Study methods, not a recommended personal regimen.

Protocol source ↗ · Publisher full-text HTML methods and results checked.

Results · Publisher full-text HTML methods and results checked.
MeasureResultComparison, timing and statistics
Primary CGI-I response · 6 mg/day57.1% versus 28.6% placeboDay 29 · p=0.0148
Primary CGI-I response · 3 / 9 mg/day39.5% / 43.9%Neither significantly exceeded placebo
Analysis populations168 intention-to-treat; 165 per protocol
Phase II primary CGI-I response
Phase II primary CGI-I response
GroupRandomizedITT responsePP response
3 mg/day4339.5%40.5%
6 mg/day4257.1%58.5%
9 mg/day4143.9%45.0%
Placebo4228.6%28.6%

Response: CGI-I 1 or 2 at day 29. ITT n=168; PP n=165. Only the 6 mg/day comparison reached significance versus placebo.

Randomized double-blind study in neurasthenia/adjustment disorders; generalized anxiety disorder was excluded. Sponsor-affiliated investigators; four-week findings do not establish long-term benefit.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
168 randomized: 3 mg/day n=43, 6 mg/day n=42, 9 mg/day n=41, placebo n=42; 165 completed per protocol.
Source reviewed
Publisher full-text HTML methods and results checked.
Study limitations
  • Randomized double-blind study in neurasthenia/adjustment disorders; generalized anxiety disorder was excluded.
  • Sponsor-affiliated investigators; four-week findings do not establish long-term benefit.

Reviewed 2026-11-01.

Read the source ↗

Randomized study in people · 2024

Ranquilon in anxiety associated with neurasthenia and adjustment disorder: randomized double-blind placebo-controlled phase III trial

At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.

Study notes and original source
2024Randomized trialFull text available

Ranquilon in anxiety associated with neurasthenia and adjustment disorder: randomized double-blind placebo-controlled phase III trial

GB-115 / Ranquilon (L-tryptophan dipeptide derivative) · Original journal publication

T. A. Karavayeva, E. M. Krupitsky, A. N. Barinov, L. G. Kolik, K. A. Ishchenko, K. K. Khacheva · V.M. Bekhterev Review of Psychiatry and Medical Psychology. 58(4-2):78–99

At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.

Results and tables

Reported findings and study design

At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.

Population or model 220 adults, 110 Ranquilon and 110 placebo; 28 days of treatment.

Dose, route and schedule

Ranquilon 6 mg/day orally (2 mg three times daily) or matching placebo for 28 days. Study methods, not a recommended personal regimen.

Protocol source ↗ · Original 22-page journal PDF: methods, bilingual summary and selected numerical results checked.

Results · Original 22-page journal PDF: methods, bilingual summary and selected numerical results checked.
MeasureResultComparison, timing and statistics
Primary ≥50% HARS response77/110 (70.0%) versus 27/110 (24.5%)Day 29 ± 1 · p<0.0001
Response-rate difference45.5 percentage pointsAbsolute difference, not a 45.5% relative reduction
HARS decrease · day 2911.90 ± 4.88 versus 5.43 ± 5.03 pointsp<0.0001
Patients with adverse events28/110 (25.5%) versus 16/110 (14.6%)p=0.063
Adverse-event counts43 active-arm events; 21 placebo-arm eventsNo serious events or adverse-event discontinuations reported
Phase III reported comparisons
Phase III reported comparisons
EndpointRanquilon (n=110)Placebo (n=110)Comparison
HARS response ≥50%, day 1532 (29.1%)6 (5.5%)p<0.0001
HARS response ≥50%, day 2977 (70.0%)27 (24.5%)p<0.0001
HARS decrease, day 157.47 ± 5.112.91 ± 3.04p<0.0001
HARS decrease, day 2911.90 ± 4.885.43 ± 5.03p<0.0001
Patients with adverse events28 (25.5%)16 (14.6%)p=0.063

HARS decreases are mean ± SD points. Response and adverse-event denominators are patients; event totals are separate.

Neurasthenia and adjustment disorders; do not relabel this as a generalized-anxiety-disorder trial. Valenta-funded report with sponsor-affiliated authors; 28-day efficacy and safety require longer independent follow-up.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
220 adults, 110 Ranquilon and 110 placebo; 28 days of treatment.
Source reviewed
Original 22-page journal PDF: methods, bilingual summary and selected numerical results checked.
Study limitations
  • Neurasthenia and adjustment disorders; do not relabel this as a generalized-anxiety-disorder trial.
  • Valenta-funded report with sponsor-affiliated authors; 28-day efficacy and safety require longer independent follow-up.

Reviewed 2026-11-01.

Read the source ↗

Randomized study in people · 2026

Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison

The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).

Study notes and original source
2026Randomized trialRussian-language source

Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison

GB-115 / Ranquilon (L-tryptophan dipeptide derivative) · Original journal publication

T. A. Karavayeva, A. N. Barinov, I. V. Egorov, E. Yu. Ebzeeva, K. A. Ishchenko · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 126(7):51–62

The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).

Results and tables

Reported findings and study design

The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).

Population or model 200 randomized: Ranquilon 100; Afobazol 100.

Dose, route and schedule

Ranquilon 6 mg/day or Afobazol (fabomotizole) 30 mg/day orally for 28 days. Study methods, not a recommended personal regimen.

Protocol source ↗ · Publisher abstract and references checked; full 2026 article not accessed.

Results · Publisher abstract and references checked; full 2026 article not accessed.
MeasureResultComparison, timing and statistics
Reported ≥50% HARS response63.3% (62 patients) versus 49.0% (49 patients)Day 29 · p<0.043
Arm-level patients with adverse events16/100 versus 12/100Overall count in abstract is inconsistent; arm-level figures retained as printed · p=0.4150

Active-comparator, open-label trial; this is not a blinded placebo comparison. The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
200 randomized: Ranquilon 100; Afobazol 100.
Source reviewed
Publisher abstract and references checked; full 2026 article not accessed.
Study limitations
  • Active-comparator, open-label trial; this is not a blinded placebo comparison.
  • The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2007

CCK-4 dipeptide analogue design: opposite behavioral effects of L- and D-tryptophan derivatives

L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.

Study notes and original source
2007Animal / experimentalEnglish abstract

CCK-4 dipeptide analogue design: opposite behavioral effects of L- and D-tryptophan derivatives

GB-115 and related L-/D-tryptophan analogues · Original journal publication

Gudasheva TA, Kir'ianova EP, Kolik LG, Konstantinopol'skiĭ MA, Seredenin SB · Bioorg Khim 33:413-420

L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.

Results and tables

Reported findings and study design

L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.

Population or model Medicinal-chemistry series and rat anxiety models.

Results · Primary indexed English abstract checked.
MeasureResultComparison, timing and statistics
Rat anxiety-model activity0.05–0.2 mg/kg GB-115; opposite effects in L/D series

Stereochemical findings are from animal experiments; D-GB-115 and GB-115 are distinct compounds.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Medicinal-chemistry series and rat anxiety models.
Source reviewed
Primary indexed English abstract checked.
Study limitations
  • Stereochemical findings are from animal experiments; D-GB-115 and GB-115 are distinct compounds.

Reviewed 2026-11-01.

Read the source ↗

Randomized study in people · 1991

Dose-ranging CCK-4 panic-challenge study in healthy volunteers

Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.

CCK-4 panic incidence · 11% / 17% / 47% across increasing doses; 0 with placebo

Study notes and original source
1991Randomized trialEnglish abstract

Dose-ranging CCK-4 panic-challenge study in healthy volunteers

CCK-4 (tetragastrin); no GB-115 administered · Original journal publication

Bradwejn J, Koszycki D, Bourin M · J Psychiatry Neurosci 16:91-95

Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.

Results and tables

Reported findings and study design

Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.

Population or model 36 healthy volunteers in randomized double-blind challenge conditions.

Results · Primary indexed English abstract checked.
MeasureResultComparison, timing and statistics
CCK-4 panic incidence11% / 17% / 47% across increasing doses; 0 with placebo

CCK-4 challenge experiment, not GB-115 administration or an anxiety-treatment trial.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
36 healthy volunteers in randomized double-blind challenge conditions.
Source reviewed
Primary indexed English abstract checked.
Study limitations
  • CCK-4 challenge experiment, not GB-115 administration or an anxiety-treatment trial.

Reviewed 2026-11-01.

Read the source ↗

Observational study · 2019

[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].

A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.

Study notes and original source
2019Uncontrolled human reportEnglish abstract

[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].

Neznamov GG, Dorofeeva OA, Metlina MV, Syunyakov TS, Minaev SV, Ivashkina NY, Martyanov VA, Seredenin SB · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.

Results and tables

Reported findings and study design

A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.

31 adults with generalized anxiety disorder, aged 22–53: 22 women, 9 men.

Dose, route and schedule

GB-115 was studied as 1 mg tablets during 21 days of treatment. The authors identified 6 mg/day as the effective dose in this report; the abstract does not give a divided-dose schedule.

Protocol source ↗ · Indexed publication abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Anxiety and cognitive measuresReported favorable changes; no numerical scale deltas in indexed abstract
Participants31 (22 women; 9 men)
Studied dose and durationEffective dose described as 6 mg/day; 21 days

This pilot is distinct from the larger phase II/III reports, and possible overlap with later 25-person conference analyses remains flagged.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
31 adults with generalized anxiety disorder
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Uncontrolled pilot evidence; expectancy and repeated-testing effects remain possible.
  • Later 25-patient conference analyses may overlap and are not counted as independent replication.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2013

Anxiolytic activity of dipeptide GB-115 after oral administration.

Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.

Study notes and original source
2013Animal / experimentalEnglish abstract

Anxiolytic activity of dipeptide GB-115 after oral administration.

Kolik LG, Konstantinopolsky MA, Ryibina IV, Povarnina PY, Gudasheva TA, Seredenin SB · Bulletin of experimental biology and medicine

Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.

Population / setting
Rodents; open-field and elevated-plus-maze experiments
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2012

Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.

GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.

Study notes and original source
2012Animal / experimentalEnglish abstract

Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.

Kolik LG, Gudasheva TA, Seredenin SB · Bulletin of experimental biology and medicine

GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.

Population / setting
Rats and BALB/c and C57Bl/6 mice
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Review of earlier studies · 2018

Novel Technologies for Dipeptide Drugs Design and their Implantation.

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Study notes and original source
2018ReviewEnglish abstract

Novel Technologies for Dipeptide Drugs Design and their Implantation.

Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Population / setting
Developer account of medicinal-chemistry programs
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Developer review; claims require appraisal of each original study.
  • A shared design method does not establish equivalent biology or clinical benefit.

Reviewed 2026-10-05.

Read the source ↗

Observational study · 2022

Clinical effects of GB-115 in patients with Generalized Anxiety Disorder

A conference post-hoc analysis of 25 patients reported lower anxiety and fatigue scores over 21 days. Its relationship to the earlier pilot must be resolved before treating it as independent evidence.

Study notes and original source
2022Uncontrolled human reportFull text available

Clinical effects of GB-115 in patients with Generalized Anxiety Disorder

· Conference abstract

· European Psychiatry. 65(Suppl 1):S388

A conference post-hoc analysis of 25 patients reported lower anxiety and fatigue scores over 21 days. Its relationship to the earlier pilot must be resolved before treating it as independent evidence.

Population / setting
25 patients; uncontrolled conference report
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Conference abstract, not a full clinical report.
  • No placebo comparison; possible overlap with the 31-patient pilot.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗